Found 14 of ic50 for monomerid = 572192 TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 41nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 44nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 44nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetApoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
TargetApoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
TargetApoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
